Home > Healthcare > Pharmaceuticals > Finished Drug Form > Intravenous Iron Drugs Market

Intravenous Iron Drugs Market Share

Report ID: GMI10898
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Intravenous Iron Drugs Market Share

The market is highly competitive, with a mix of major global companies and smaller to medium-sized firms vying for market share. A key aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. These leading companies play a crucial role in shaping the market's trajectory. In addition to research and development efforts, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding the global footprint of prominent players. Meanwhile, smaller companies focus on specific drug types to compete with established vendors.

Intravenous Iron Drugs Market Companies

Some of the eminent market participants operating in the intravenous iron drugs industry include:

AbbVie Inc.
AdvaCare Pharma
Akebia Therapeutics, Inc.
AMAG Pharmaceuticals. Inc.
Bayer AG
Covis Pharma GmbH
CSL Limited
Daiichi Sankyo Company, Ltd.
F. Hoffmann-La Roche Ltd.
Fresenius SE & Co. KGaA
Novartis AG
PHARMACOSMOS A/S
Rockwell Medical, Inc.
Sanofi
Zydus Lifesciences Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Intravenous iron drugs industry was valued at USD 1.7 billion in 2023 and is estimated to grow at 6.7% CAGR from 2024 to 2032 due to strong usage to treat or prevent iron deficiency anemia

The chronic kidney disease application segment accounted for USD 1 billion in 2023 as they provide a more direct and efficient way to replenish iron levels.

U.S intravenous iron drugs industry is projected to reach USD 1 billion by 2032 owing to well-developed healthcare infrastructure, including state-of-the-art hospitals and specialized clinics

AbbVie Inc., AdvaCare Pharma, Akebia Therapeutics, Inc., Bayer AG, Covis Pharma GmbH, CSL Limited, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, Novartis AG, PHARMACOSMOS A/S, Rockwell Medical, Inc., Sanofi, and Zydus Lifesciences Limited